

PAR 2 Inhibitors

Published date: July 11, 2018

Technology description

Invention

This invention describes new inhibitors of the protease activated receptor 2 (PAR2), a G protein coupled receptor (GPCR) involved in inflammatory related diseases, for the treatment of asthma and a wide range of other diseases.

Background

It is estimated that by 2025 400 million people will be suffering from asthma. While the prevalence of asthma is increasing, treatments for asthma have remained constant over the past several decades. These treatments provide control for only approximately half of asthma patients. There needs to be drugs developed that allow patients to have more control over their asthma.

Application area

Drugs for the treatment of asthma

Potential for use in a variety of other inflammatory diseases including chronic pain, cancer, and vascular disorders

Advantages

Potential to allow patients to control their allergen induced asthma

Institution

[University of Arizona](#)

Inventors

[Theodore Price](#)

Associate Professor

[Scott Boitano](#)

Professor

Physiology

[Josef Vagner](#)

Associate Research Professor
BIO5 Institute

联系我们



叶先生

电话 : 021-65679356

手机 : 13414935137

邮箱 : yeyingsheng@zf-ym.com